Haemnet Showcases Research on Severe Haemophilia A Patients Adapting to Emicizumab Therapy
Haemnet posted on LinkedIn:
”Shared decision-making is a real buzzword in modern haemophilia care. But how do you ensure that it moves beyond lip service to truly empower patients in decisions about their treatment?
This question underlies a new paper in The Journal of Haemophilia Practice, exploring the experience of people with haemophilia A switching from factor VIII prophylaxis to emicizumab.
The authors conducted in-depth qualitative interviews with participants with severe haemophilia A without FVIII inhibitors from the Swedish cohort of the HemiNorth 2 study. Alongside the process of ‘adapting to a new reality’ and a sense of normality, they found that ‘shattered expectations’ emerged as a key theme, highlighting gaps in knowledge among the patient group and the need to ensure that appropriate, patient-friendly information dis available to support treatment decisions.
Find out more, open access, in The Journal of Haemophilia
Practice here.”
Title: Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab
Authors: Linda Myrin-Westesson, Anna Olsson
Stay updated with Hemostasis Today.
-
Sep 18, 2025, 06:50Fetal Hereditary TTP Featured in NEJM – Senior Author Nishant Rajendra Tiwari
-
Sep 17, 2025, 10:54Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
-
Sep 17, 2025, 08:16Superficial Vein Thrombosis Management: John Fanikos Shares Latest Review
-
Sep 17, 2025, 07:00Maha Othman - ''BIC 2025 is Without a Doubt a Remarkable Scientific Event — and I’m Excited for What Lies Ahead!''
-
Sep 16, 2025, 11:17Glenn Pierce: WHO Issues a Biannual Essential Medicines List
-
Sep 18, 2025, 07:00Rishabh Singh on NEJM Letter: FVIII Aurora Mutation Shows Increased Activity and Reduced APC Response
-
Sep 18, 2025, 02:25Flora Peyvandi Highlights 'Inflammatory Memory of Stem Cells' – New Insights for Hematologic Diseases
-
Sep 17, 2025, 16:32Endovascular Today: Dr. Eric Secemsky Analyzes Impact of Paclitaxel Pause on Peripheral Artery Disease Care
-
Sep 17, 2025, 16:28Haemnet Showcases Research on Severe Haemophilia A Patients Adapting to Emicizumab Therapy
-
Sep 17, 2025, 16:19Todd Villines: Coronary Artery Disease - A BIG Movement to Change
-
Sep 16, 2025, 14:59A New Era in Antiplatelet Therapy for CABG?
-
Sep 16, 2025, 07:44Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
-
Sep 16, 2025, 02:44Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 18, 2025, 06:34'A New Era in Mechanical Thrombectomy?' – Sripal Bangalore Highlights SYMPHONY-PE IDE Study
-
Sep 17, 2025, 10:49Living with Glanzmann Thrombasthenia․ Eliza VanZweden’s Story of Resilience and Advocacy
-
Sep 17, 2025, 10:22Abdul Mannan: Turning Medical Podcasts into Active Learning with Structured Tools
-
Sep 17, 2025, 09:43Global Blood Supply Under Threat: David McIntosh Calls for Action to Support Transfusion Services
-
Sep 17, 2025, 09:08Coronary Arteries, Pericardial Cavity, and the Hidden Danger of Cardiac Tamponade During PCI-By Ahmed Ata